Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio

Bone

Volumn 72, Issue , 2015, Pages 14-22

  Tudpor, Kukiat ^a   van der Eerden, Bram C J ^b   Jongwattanapisan, Prapaporn ^a   Roelofs, Joris J T H ^c   van Leeuwen, Johannes P T M ^b   Bindels, René J M ^a   Hoenderop, Joost G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Osteoblast; Osteopetrosis; Osteoprotegerin; Receptor activator of nuclear factor B ligand; Thrombin receptor

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; DEOXYPYRIDINOLINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN P42; THROMBIN RECEPTOR; CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THROMBIN; TNFRSF11B PROTEIN, HUMAN; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTITHROMBIN DEFICIENCY; ARTICLE; BONE MASS; BONE METABOLISM; BONE REMODELING; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); CROSS LINKING; FEMUR; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBIN RECEPTOR DEFICIENCY; TRABECULAR BONE; 3T3 CELL LINE; ANIMAL; BONE; C57BL MOUSE; CACO 2 CELL LINE; CHEMISTRY; DEFICIENCY; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; BONE AND BONES; BONE RESORPTION; CACO-2 CELLS; CALCIUM; FEMUR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OSTEOBLASTS; OSTEOPROTEGERIN; PHENOTYPE; POLYMERASE CHAIN REACTION; RANK LIGAND; RECEPTORS, THROMBIN; SIGNAL TRANSDUCTION; THROMBIN; X-RAY MICROTOMOGRAPHY;

EID: 84912059785     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.11.004     Document Type: Article

References (55)

1. Li B., Ling Chau J.F., Wang X., Leong W.F. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J Cell Biochem 2011, 112:1229-1242.
2. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999, 14:1654-1663.
3. Baron R., Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metabol 2012, 97:311-325.
4. Boyce B.F., Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 2007, 5:98-104.
5. Georges S., Ruiz Velasco C., Trichet V., Fortun Y., Heymann D., Padrines M. Proteases and bone remodelling. Cytokine Growth Factor Rev 2009, 20:29-41.
6. Pagel C.N., Sivagurunathan S., Loh L.H., Tudor E.M., Pike R.N., Mackie E.J. Functional responses of bone cells to thrombin. Biol Chem 2006, 387:1037-1041.
7. Karlstrom E., Norgard M., Hultenby K., Somogyi-Ganss E., Sugars R., Andersson G., et al. Localization and expression of prothrombin in rodent osteoclasts and long bones. Calcif Tissue Int 2011, 88:179-188.
8. Sun W.Y., Witte D.P., Degen J.L., Colbert M.C., Burkart M.C., Holmback K., et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998, 95:7597-7602.
9. Senger D.R., Perruzzi C.A., Papadopoulos-Sergiou A., Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 1994, 5:565-574.
10. Sivagurunathan S., Pagel C.N., Loh L.H., Wijeyewickrema L.C., Pike R.N., Mackie E.J. Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism. J Mol Endocrinol 2013, 50:347-359.
11. Song S.J., Pagel C.N., Campbell T.M., Pike R.N., Mackie E.J. The role of protease-activated receptor-1 in bone healing. Am J Pathol 2005, 166:857-868.
12. Karlstrom E., Norgard M., Hultenby K., Somogyi-Ganss E., Sugars R., Andersson G., Wendel M. Localization and expression of prothrombin in rodent osteoclasts and long bones. Calcif Tissue Int 2011, 88:179-188.
13. Bluteau G., Pilet P., Bourges X., Bilban M., Spaethe R., Daculsi G., et al. The modulation of gene expression in osteoblasts by thrombin coated on biphasic calcium phosphate ceramic. Biomaterials 2006, 27:2934-2943.
14. Abraham L.A., MacKie E.J. Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1. J Bone Miner Res 1999, 14:1320-1329.
15. Tokuda H., Kato K., Natsume H., Kondo A., Kuroyanagi G., Matsushima-Nishiwaki R., et al. Involvement of AMP-activated protein kinase in thrombin-stimulated interleukin 6 synthesis in osteoblasts. J Mol Endocrinol 2012, 49:47-55.
16. Kaufmann R., Schafberg H., Rudroff C., Nowak G. Thrombin receptor activation results in calcium signaling and protein kinase C-dependent stimulation of DNA synthesis in HEp-2g laryngeal carcinoma cells. Cancer 1997, 80:2068-2074.
17. Gustafson G.T., Lerner U. Thrombin, a stimulator of bone resorption. Biosci Rep 1983, 3:255-261.
18. Hoffmann O., Klaushofer K., Koller K., Peterlik M., Mavreas T., Stern P. Indomethacin inhibits thrombin-, but not thyroxin-stimulated resorption of fetal rat limb bones. Prostaglandins 1986, 31:601-608.
19. Renkema K.Y., Velic A., Dijkman H.B., Verkaart S., van der Kemp A.W., Nowik M., et al. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. J Am Soc Nephrol 2009, 20:1705-1713.
20. Hoenderop J.G., Muller D., Van Der Kemp A.W., Hartog A., Suzuki M., Ishibashi K., et al. Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001, 12:1342-1349.
21. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
22. 2+ channel TRPV5 is essential for proper osteoclastic bone resorption. Proc Natl Acad Sci U S A 2005, 102:17507-17512.
23. Gruber H.E. Adaptations of Goldner's Masson trichrome stain for the study of undecalcified plastic embedded bone. Biotech Histochem 1992, 67:30-34.
24. de Groot T., Lee K., Langeslag M., Xi Q., Jalink K., Bindels R.J., et al. Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol 2009, 20:1693-1704.
25. Van Baal J., Yu A., Hartog A., Fransen J.A., Willems P.H., Lytton J., et al. Localization and regulation by vitamin D of calcium transport proteins in rabbit cortical collecting system. Am J Physiol 1996, 271:F985-F993.
26. Charoenphandhu N., Tudpor K., Pulsook N., Krishnamra N. Chronic metabolic acidosis stimulated transcellular and solvent drag-induced calcium transport in the duodenum of female rats. Am J Physiol Gastrointest Liver Physiol 2006, 291:G446-G455.
27. Vetrano S., Ploplis V.A., Sala E., Sandoval-Cooper M., Donahue D.L., Correale C., et al. Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proc Natl Acad Sci U S A 2011, 108:19830-19835.
28. O'Brien C.A., Gubrij I., Lin S.C., Saylors R.L., Manolagas S.C. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999, 274:19301-19308.
29. Daci E., Everts V., Torrekens S., Van Herck E., Tigchelaar-Gutterr W., Bouillon R., et al. Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 2003, 18:1167-1176.
30. Furlan F., Galbiati C., Jorgensen N.R., Jensen J.E., Mrak E., Rubinacci A., et al. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res 2007, 22:1387-1396.
31. Kanno Y., Ishisaki A., Kawashita E., Chosa N., Nakajima K., Nishihara T., et al. Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function. J Biol Chem 2011, 286:8952-8960.
32. van Ruijven L.J., Giesen E.B., Mulder L., Farella M., van Eijden T.M. The effect of bone loss on rod-like and plate-like trabeculae in the cancellous bone of the mandibular condyle. Bone 2005, 36:1078-1085.
33. Popp A.W., Windolf M., Senn C., Tami A., Richards R.G., Brianza S., et al. Prediction of bone strength at the distal tibia by HR-pQCT and DXA. Bone 2012, 50:296-300.
34. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007, 9(Suppl. 1):S1.
35. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
36. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
37. Shevde N.K., Plum L.A., Clagett-Dame M., Yamamoto H., Pike J.W., DeLuca H.F. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A 2002, 99:13487-13491.
38. Shalhoub V., Faust J., Boyle W.J., Dunstan C.R., Kelley M., Kaufman S., et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 1999, 72:251-261.
39. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
40. Mansour A., Abou-Ezzi G., Sitnicka E., Jacobsen S.E., Wakkach A., Blin-Wakkach C. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med 2012, 209:537-549.
41. Aronovich A., Nur Y., Shezen E., Rosen C., Zlotnikov Klionsky Y., Milman I., et al. A novel role for factor VIII and thrombin/PAR1 in regulating hematopoiesis and its interplay with the bone structure. Blood 2013, 122:2562-2571.
42. Salah Z., Maoz M., Cohen I., Pizov G., Pode D., Runge M.S., et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J 2005, 19:62-72.
43. Chay C.H., Cooper C.R., Gendernalik J.D., Dhanasekaran S.M., Chinnaiyan A.M., Rubin M.A., et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002, 60:760-765.
44. Thomas G.P., Baker S.U., Eisman J.A., Gardiner E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 2001, 170:451-460.
45. Aguirre-Ghiso J.A., Liu D., Mignatti A., Kovalski K., Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001, 12:863-879.
46. Camerer E., Barker A., Duong D.N., Ganesan R., Kataoka H., Cornelissen I., et al. Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell 2010, 18:25-38.
47. Hu H., Yamashita S., Hua Y., Keep R.F., Liu W., Xi G. Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway. Brain Res 2010, 1361:93-101.
48. Wysoczynski M., Liu R., Kucia M., Drukala J., Ratajczak M.Z. Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Mol Cancer Res 2010, 8:677-690.
49. Ruiz-Loredo A.Y., Lopez E., Lopez-Colome A.M. Thrombin stimulates stress fiber assembly in RPE cells by PKC/CPI-17-mediated MLCP inactivation. Exp Eye Res 2012, 96:13-23.
50. Amiable N., Martel-Pelletier J., Lussier B., Kwan Tat S., Pelletier J.P., Boileau C. Proteinase-activated receptor-2 gene disruption limits the effect of osteoarthritis on cartilage in mice: a novel target in joint degradation. J Rheumatol 2011, 38:911-920.
51. Yoshitake F., Itoh S., Narita H., Ishihara K., Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 2008, 283:11535-11540.
52. Barnhart M.I. Cellular site for prothrombin synthesis. Am J Physiol 1960, 199:360-366.
53. Karlstrom E., Ek-Rylander B., Wendel M., Andersson G. RANKL induces components of the extrinsic coagulation pathway in osteoclasts. Biochem Biophys Res Commun 2010, 394:593-599.
54. Tudpor K., Lainez S., Kwakernaak A.J., Kovalevskaya N.V., Verkaart S., van Genesen S., et al. Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria. J Am Soc Nephrol 2012, 23:1824-1834.
55. Swystun V.A., Renaux B., Moreau F., Wen S., Peplowski M.A., Hollenberg M.D., et al. Serine proteases decrease intestinal epithelial ion permeability by activation of protein kinase Czeta. Am J Physiol Gastrointest Liver Physiol 2009, 297:G60-G70.